Biotech: The “safe” drug bet?
Biotech: The “safe” drug bet? “Defensive pharma stocks have struggled while biotechs have flourished. Can this continue?”
Biotech: The “safe” drug bet? “Defensive pharma stocks have struggled while biotechs have flourished. Can this continue?”
Biotech execs have a sense of humor about elusive profits When Ernst & Young’s annual report on the biotechnology industry last year predicted that as a whole, the industry would turn profitable for the first time in 2008, some long-term industry veterans gave a knowing heard-that-one-before chuckle.